Supplements to Avoid with Letrozole
There are no specific supplements that must be avoided with letrozole; however, vitamin D and calcium supplementation are actually recommended to mitigate bone loss and musculoskeletal side effects associated with aromatase inhibitor therapy.
Recommended Supplements During Letrozole Treatment
The evidence strongly supports supplementation rather than avoidance when taking letrozole:
Vitamin D and Calcium - Actively Recommended
Vitamin D deficiency (63-86% of patients) is extremely common in women taking letrozole and contributes significantly to the musculoskeletal symptoms that affect 50-69% of patients 1.
Supplementation protocol based on evidence:
Clinical benefits demonstrated:
- Significantly reduced letrozole-induced arthralgia and joint pain disability 3, 2
- Women with vitamin D levels >66 ng/mL had 52% report no disability from joint pain versus only 19% with lower levels (p=0.026) 2
- Improved musculoskeletal symptom scores (9.14 vs 8.10, p<0.001) 3
- Decreased bone loss risk - letrozole increases osteoporosis risk from 6% to 11-21% 1
Bone Health Monitoring
ASCO guidelines specifically recommend 4:
- Resistance exercise
- Vitamin D and calcium supplements
- Bone-modifying agents when indicated
- DEXA scans for monitoring
Important Caveats
No Evidence of Harmful Supplement Interactions
The FDA label for letrozole does not list any supplement contraindications 5. The primary concerns with letrozole relate to:
- Pregnancy (absolute contraindication) - causes fetal harm
- Drug-drug interactions are not extensively documented in the provided evidence
Estrogen-Containing Supplements - Theoretical Concern
While not explicitly stated in the guidelines, avoid phytoestrogens or estrogen-containing supplements as they would theoretically counteract letrozole's mechanism of action (aromatase inhibition to reduce estrogen). This is based on pharmacologic principles rather than direct evidence from the studies provided.
Side Effect Profile to Monitor
Letrozole increases risk of 1:
- Bone fractures (NNH=72)
- Cardiovascular events (NNH=122)
- New osteoporosis (6% placebo vs 11% letrozole, p<0.001)
- Arthralgia (50-69% of patients)
The evidence overwhelmingly supports proactive vitamin D and calcium supplementation rather than supplement avoidance, with the only theoretical exception being estrogen-mimicking compounds that would undermine the drug's therapeutic mechanism.